China's medical products administrator approved Jiangsu CoWin Biotech's (SHA:688426) influenza A/B and respiratory syncytial virus nucleic acid detection kit, according to a Tuesday filing with the Shanghai Stock Exchange.
The kits use fluorescence polymerase chain reaction methods through swab samples from the pharynx, the filing said.